S Loi Selected Research

S Loi Research Topics

Disease

20	Breast Neoplasms (Breast Cancer) 04/2024 - 12/2012
13	Triple Negative Breast Neoplasms 12/2021 - 08/2014
13	Neoplasms (Cancer) 10/2021 - 02/2013
2	Brain Neoplasms (Brain Tumor) 07/2023 - 01/2022
1	Lung Neoplasms (Lung Cancer) 04/2024
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024
1	Pathologic Complete Response 01/2019
1	Residual Neoplasm 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017
1	Disease Progression 01/2016
1	Pain (Aches) 01/2016
1	Cystic Fibrosis (Mucoviscidosis) 02/2013
1	Hypoxia (Hypoxemia) 02/2005
1	Rectal Neoplasms (Rectal Cancer) 02/2005
1	HIV Infections (HIV Infection) 05/2004
1	Multi-centric Castleman's Disease 05/2004
1	Malnutrition (Nutritional Deficiencies) 03/2001

Drug/Important Bio-Agent (IBA)

7	Trastuzumab (Herceptin)FDA Link 10/2023 - 08/2014
6	Hormones (Hormone)IBA 01/2024 - 01/2016
6	Biomarkers (Surrogate Marker)IBA 10/2023 - 02/2015
5	atezolizumabIBA 12/2021 - 01/2020
4	human ERBB2 proteinIBA 04/2024 - 02/2013
4	130-nm albumin-bound paclitaxelIBA 12/2021 - 01/2020
3	B7-H1 AntigenIBA 01/2021 - 01/2020
3	pembrolizumabIBA 01/2020 - 01/2019
3	Lapatinib (GW572016)FDA Link 01/2019 - 01/2016
2	tucatinibIBA 07/2023 - 01/2022
2	Capecitabine (Xeloda)FDA Link 07/2023 - 01/2022
2	Hematoxylin (Haematoxylon)IBA 10/2021 - 02/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 10/2021 - 02/2015
2	Estrogen ReceptorsIBA 10/2020 - 10/2016
2	Phenobarbital (Luminal)FDA Link 01/2017 - 12/2012
1	sacituzumab govitecanIBA 04/2024
1	trastuzumab deruxtecanIBA 04/2024
1	telisotuzumab vedotinIBA 04/2024
1	patritumab deruxtecanIBA 04/2024
1	Ado-Trastuzumab EmtansineIBA 04/2024
1	Surface Antigens (Surface Antigen)IBA 04/2024
1	Immunoconjugates (Immunoconjugate)IBA 04/2024
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2024
1	Methotrexate (Mexate)FDA LinkGeneric 01/2024
1	ErbB Receptors (EGF Receptor)IBA 01/2023
1	Estrogens (Estrogen)FDA Link 10/2021
1	Letrozole (Femara)FDA LinkGeneric 10/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	cobimetinibIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2019
1	LigandsIBA 10/2018
1	olaparibIBA 08/2018
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Formaldehyde (Formol)FDA Link 01/2018
1	ParaffinIBA 01/2018
1	Fulvestrant (Faslodex)FDA Link 01/2016
1	palbociclibIBA 01/2016
1	pertuzumabIBA 02/2013
1	Docosahexaenoic AcidsIBA 02/2013
1	Fluorine-18IBA 02/2005
1	Deoxyglucose (2 Deoxy D glucose)IBA 02/2005
1	Fluorouracil (Carac)FDA LinkGeneric 02/2005
1	MisonidazoleIBA 02/2005
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2005
1	fluoromisonidazoleIBA 02/2005

Therapy/Procedure

5	Therapeutics 10/2020 - 08/2018
4	Drug Therapy (Chemotherapy) 01/2021 - 01/2016
2	Adjuvant Chemotherapy 01/2024 - 12/2019
2	Neoadjuvant Therapy 01/2020 - 01/2019
1	Precision Medicine 01/2019
1	Immunotherapy 01/2017
1	Radiotherapy 02/2005
1	Highly Active Antiretroviral Therapy (HAART) 05/2004
1	Peritoneal Dialysis 03/2001